Publications by authors named "Dennis M Bonal"

17Publications

Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.

Cancer Cell 2019 11 17;36(5):528-544.e10. Epub 2019 Oct 17.

Division of Newborn Medicine and Epigenetics Program, Department of Medicine, Boston Children's Hospital, Boston, MA 02115, USA; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.09.005DOI Listing
November 2019

Development and validation of a new MRI simulation technique that can reliably estimate optimal in vivo scanning parameters in a glioblastoma murine model.

PLoS One 2018 23;13(7):e0200611. Epub 2018 Jul 23.

Department of Imaging, Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0200611PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056046PMC
January 2019

PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.

Cancer Med 2015 Aug 29;4(8):1258-71. Epub 2015 May 29.

Department of Pathology, Icahn School of Medicine at Mount Sinai, New York City, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.463DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559037PMC
August 2015

ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer.

J Urol 2015 Apr 28;193(4):1144-50. Epub 2014 Oct 28.

Department of Pathology, Columbia University, New York, New York; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2014.10.098DOI Listing
April 2015

Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer.

PLoS One 2014 4;9(6):e98786. Epub 2014 Jun 4.

Department of Pathology and Cell Biology, Columbia University, New York, New York, United States of America; Department of Urology, Columbia University, New York, New York, United States of America; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, United States of America; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0098786PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045811PMC
August 2015